CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Deregulating the activation of their components, such as Akt or Stat5 has been associated with curative efficacy in CML, suggesting that they are probable drivers of oncogenesis in the drug-resistant Bcr-Abl+ CD34+/CD38− hCSCs [29].